STRO (Sutro Biopharma) Insider Ownership: 6.25 % (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STRO Sutro Biopharma Inc STRO
45 GF Score
Price $20.46
GF Value $5.50
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Insider Ownership?

Sutro Biopharma STRO -4.16% 45 Insider Ownership is 6.25 % as of Aug. 16, 2026. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sutro Biopharma's insider ownership is 6.25%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sutro Biopharma's Institutional Ownership is 87.25%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sutro Biopharma's Float Percentage Of Total Shares Outstanding is 99.70%.

Sutro Biopharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Insider Ownership Chart

Sutro Biopharma Historical Data

The historical data trend for Sutro Biopharma can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 1.36 1.39 1.37 1.51 1.51 13.70 7.12 6.34 6.25 6.25
STRO
45GF Score
Sutro Biopharma Inc STRO
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 6.25 % mean?
Sutro Biopharma (STRO) has a Insider Ownership of 6.25 % as of Aug. 16, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Insider Ownership too high?
Sutro Biopharma's current Insider Ownership is 6.25 %. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Insider Ownership compare to AVIR and IPSC?
Sutro Biopharma's Insider Ownership of 6.25 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Insider Ownership is 6.25 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current Insider Ownership is 6.25 %. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Insider Ownership is 6.25 % as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (STRO) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for STRO:

  • Insider Ownership: 6.25 %
  • GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges S090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STRO

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.46
Price
$5.50
GF Value